{"id":994709,"date":"2026-08-13T07:18:18","date_gmt":"2026-08-13T11:18:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/"},"modified":"2026-08-13T07:18:18","modified_gmt":"2026-08-13T11:18:18","slug":"liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/","title":{"rendered":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FULLERTON, Calif., Aug.  13, 2026  (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the\u00a0<strong>Nasdaq Capital Market, effective August 4, 2026<\/strong>, and that the Nasdaq Hearings Panel (the \u201cPanel\u201d) has granted the Company additional time to demonstrate compliance with Nasdaq\u2019s minimum bid price requirement.<\/p>\n<p>The transfer to the Nasdaq Capital Market allows the Company\u2019s common stock to continue trading on Nasdaq under its existing ticker symbol, <strong>\u201cLIMN.\u201d<\/strong> The Nasdaq Capital Market is one of Nasdaq\u2019s three listing tiers.<\/p>\n<p>In addition, the Panel has granted the Company\u2019s request for an extension to demonstrate compliance with the applicable minimum bid price requirement. Under the Panel\u2019s decision, the Company has until <strong>September 3, 2026<\/strong> to demonstrate compliance with the Bid Price Rule.<\/p>\n<p>The Company intends to take the actions necessary to regain compliance with the minimum bid price requirement within the period granted by the Panel. The Company\u2019s common stock will continue to trade on the Nasdaq Capital Market during this period, subject to the Company\u2019s compliance with the Panel\u2019s decision and other applicable Nasdaq continued listing requirements.<\/p>\n<p>\u201cWe are pleased to have completed the transfer to the Nasdaq Capital Market and appreciate the Panel providing the Company additional time to demonstrate compliance with the minimum bid price requirement,\u201d said <strong>Scott Dam, Chief Financial Officer of Liminatus Pharma<\/strong>. \u201cMaintaining our Nasdaq listing remains an important priority as we continue executing on our corporate and clinical development strategy.\u201d<\/p>\n<p>\n        <strong>About Liminatus Pharma, Inc.<\/strong>\n      <\/p>\n<p>Liminatus Pharma, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The Company\u2019s development portfolio includes IBA101, a humanized anti-CD47 monoclonal antibody being developed as a next-generation immune-modulating cancer therapy, together with additional therapeutic assets acquired through the Company\u2019s strategic transactions.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, among other things, statements regarding the Company\u2019s ability to regain compliance with Nasdaq\u2019s continued listing requirements, the timing and effectiveness of actions taken to regain compliance, the Company\u2019s continued listing on the Nasdaq Capital Market, and the Company\u2019s corporate and clinical development plans. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no assurance that the Company will regain compliance with the minimum bid price requirement within the period granted by the Panel or maintain compliance with other applicable Nasdaq listing requirements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.<\/p>\n<p>For more information, please contact:<\/p>\n<p>Chris Kim, Chief Executive Officer<br \/>chris@liminatus.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2I3YWQzYWMtNmZhMS00ZTk4LTgwZTItYjNhNTIyZDA2NmE5LTEzMTU0NzUtMjAyNi0wOC0xMy1lbg==\/tiny\/Liminatus-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the\u00a0Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the \u201cPanel\u201d) has granted the Company additional time to demonstrate compliance with Nasdaq\u2019s minimum bid price requirement. The transfer to the Nasdaq Capital Market allows the Company\u2019s common stock to continue trading on Nasdaq under its existing ticker symbol, \u201cLIMN.\u201d The Nasdaq Capital Market is one of Nasdaq\u2019s three listing tiers. In addition, the Panel has granted the Company\u2019s request for an extension to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-994709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the\u00a0Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the \u201cPanel\u201d) has granted the Company additional time to demonstrate compliance with Nasdaq\u2019s minimum bid price requirement. The transfer to the Nasdaq Capital Market allows the Company\u2019s common stock to continue trading on Nasdaq under its existing ticker symbol, \u201cLIMN.\u201d The Nasdaq Capital Market is one of Nasdaq\u2019s three listing tiers. In addition, the Panel has granted the Company\u2019s request for an extension to &hellip; Continue reading &quot;Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T11:18:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement\",\"datePublished\":\"2026-08-13T11:18:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/\"},\"wordCount\":487,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/\",\"name\":\"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\",\"datePublished\":\"2026-08-13T11:18:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk","og_description":"FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Liminatus Pharma, Inc. (Nasdaq: LIMN) (\u201cLiminatus\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the\u00a0Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the \u201cPanel\u201d) has granted the Company additional time to demonstrate compliance with Nasdaq\u2019s minimum bid price requirement. The transfer to the Nasdaq Capital Market allows the Company\u2019s common stock to continue trading on Nasdaq under its existing ticker symbol, \u201cLIMN.\u201d The Nasdaq Capital Market is one of Nasdaq\u2019s three listing tiers. In addition, the Panel has granted the Company\u2019s request for an extension to &hellip; Continue reading \"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-13T11:18:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement","datePublished":"2026-08-13T11:18:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/"},"wordCount":487,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/","name":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=","datePublished":"2026-08-13T11:18:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTM3MyM3Nzc0NjMyIzIzMDM5MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-to-regain-compliance-with-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=994709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=994709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=994709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=994709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}